

), (- -1 (-1), (), - 6 (-6) [4],
[5]. [6].

- [7].

(-1 , -6, -)
[8],

[9].

-1 , - , [10].

: ()/ ()

: 50 -

(1999). (CR, 1990, 1991), -

-14 . / 150 12 :
(n=26) -

/ (500 /500) 1 (n=24) -
/ 1 50

20 .

: , ,

WOMAC. (-1 ,
 -6, -0)
 « » () « » ()
 3
 Microsoft Office 2000
 (. 8318137 28.05.2008).

:
 -1 4,7 (<0,001), -6 - 3,3 (<0,001),
 - - 5 (<0,001) ().
 -1 (<0,001),
 (- <0,01).
 -6
 : 3,0
 (<0,001) 1,7 , (- <0,001).

/	n=20			3	
		n=26	n=24	n=26	n=24
-1	15,6±0,51	71,6±3,6*	69,8±2,9*	42,32±2,16*	34,8±1,75*
-6	4,6±0,39	17,4±1,02*	16,4±0,92*	9,58±0,46*	5,76±0,26*
-	5,3±0,42	25,3±2,54*	25,1±2,46*	19,6±0,68*	11,8±0,57*
∴ ; -		(<0,05)		: * - , • -	

1,7 (- <0,05).

3

38,5%,

- 66,7% (- <0,05).
58,3%

20,7% (- <0,05).

WOMAC

14,8% , 54,2% (-
 <0,01); - 18,5% 62,5% (- <0,01); - 29,6%
 8,3% (- <0,01).
 / 63% (- <0,05).

, 3

/

, -1 , -6

- .

/

,

WOMAC,

:

1.

/

,

/ .

2.

.

1. Hochberg M.C. Mortality in osteoarthritis. Clin. Exp. Rheumat. 2008; 26(5): 120-124.

2. . . , . . , -
-

2010; 3: 35-41.

3. . . , . . , . .

- []. 2012; 1. : www.ukrcardio.org/journal.php/article/670.
4. Fernandez-Real J.M., Wifredo R. Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocrine Rive*. 2003; 24(3): 278-301.
 5. ; 2010. 608 .
 6. Engström G., Gerhardsson de Verdier M., Rollof J. et al. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. [Osteoarthritis Cartilage](#) 2009; 17(2): 168-173.
 7. -1 -6
-1
2009; 6: 52-56.
 8. 2012; 2(2): 68-73.
 9. Pasin J. S., Ferreira A. P., Saraiva A. L. et al. Diacerein decreases TNF-alpha and IL-1beta levels in peritoneal fluid and prevents Baker's yeast-induced fever in young rats. [Inflamm. Res.](#) 2010; 59(3): 189-196.
 10. Bartels E.M., Bliddal H., Schøndorff P. K. et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. [Osteoarthritis Cartilage](#) 2010; 18(3): 289-296.